Vir Biotechnology (VIR) director granted 8,000 RSUs and 16,000 options

Rhea-AI Filing Summary

Vir Biotechnology, Inc. director Janet Napolitano reported awards of company equity as part of compensation. She received 8,000 shares of Common Stock in the form of restricted stock units (RSUs) under the company’s Equity Incentive Plan. These RSUs will vest in full on May 27, 2027, meaning the shares become fully owned at that time.

She was also granted a stock option for 16,000 shares of Common Stock with an exercise price of $9.10 per share. The option will vest and become exercisable in full on May 27, 2027. Following the RSU grant, Napolitano directly holds 24,416 shares of Vir Biotechnology common stock, and holds the newly granted option covering 16,000 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Napolitano Janet

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,000	$0.00	--
Grant/Award	Common Stock	8,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,000 shares (Direct, null); Common Stock — 24,416 shares (Direct, null)

Footnotes (1)

1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. The RSUs will vest in full on May 27, 2027. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Key Figures

RSU grant: 8,000 shares Option grant size: 16,000 shares Option exercise price: $9.10/share +4 more

7 metrics

RSU grant 8,000 shares Restricted stock units granted May 27, 2026

Option grant size 16,000 shares Stock option covering common stock

Option exercise price $9.10/share Stock option strike price

RSU vesting date May 27, 2027 RSUs vest in full on this date

Option vesting date May 27, 2027 Option becomes fully exercisable on this date

Shares after RSU grant 24,416 shares Common stock directly held following transaction

Options held after grant 16,000 options Total options following transaction

Key Terms

restricted stock units (RSUs), Equity Incentive Plan, Stock Option (Right to Buy), vest in full, +1 more

5 terms

restricted stock units (RSUs) financial

"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Equity Incentive Plan financial

"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest in full financial

"The RSUs will vest in full on May 27, 2027."

exercisable in full financial

"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Napolitano Janet

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A(1)		8,000(2)	A	$0	24,416	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.1	05/27/2026		A		16,000(3)		05/27/2027	05/26/2036	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

2. The RSUs will vest in full on May 27, 2027.

3. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)